TEPEZZA (teprotumumab-trbw) for injection, for intravenous use Initial U.S. Approval: 2020

Category: .

TEPEZZA (teprotumumab-trbw) for injection, for intravenous use Initial U.S. Approval: 2020

TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease.
For Injection: 500 mg lyophilized powder in a single-dose vial for reconstitution.
Manufactured By: Horizon
Prescribing Information URL: Click Here

Access to TEPEZZA (teprotumumab-trbw) for injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards.
It is a human monoclonal antibody developed by Genmab and Roche. It binds to IGF-1R. Teprotumumab was approved for use in the United States in January 2020.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.